Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2019
December 2019, Vol 10, No 6
December 2019, Vol 10, No 6
Online First
Value-Based Care Management Medicare Program Changes for 2020 and Beyond
By
Joseph S. Bailes, MD
;
Gena Cook
Economics & Value
,
Value-Based Care
December 2019, Vol 10, No 6
Medicare models for value-based care in oncology started with the Oncology Care Model (OCM), which was launched in July 2016 and will run until June 2021.
Read Article
Genetic Profiling and Personalized Medicine in Myelodysplastic Syndromes
By
Meg Barbor, MPH
NCCN 2019 Hematologic Malignancies
December 2019, Vol 10, No 6
San Francisco, CA—Personalization of therapy in the treatment of patients with myelodysplastic syndrome (MDS) is focused primarily on risk classification of patients. Once clinical risk has been established, treatment considerations should be informed by features such as disease subtype, prognostic somatic mutations, chromosomal abnormalities, targetable somatic mutations, immunologic features, and patient factors, according to Rafael Bejar, MD, PhD, Assistant Professor of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA.
Read Article
What Is the Role of Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukemia?
By
Meg Barbor, MPH
NCCN 2019 Hematologic Malignancies
December 2019, Vol 10, No 6
San Francisco, CA—We are in a “golden age” in chronic lymphocytic leukemia (CLL), according to Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City.
Read Article
Biosimilars Are Key Components of Oncology Today: Brush Up on the Basics
By
Meg Barbor, MPH
NCCN 2019 Hematologic Malignancies
,
Biosimilars
December 2019, Vol 10, No 6
San Francisco, CA—An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. He discussed this topic at the NCCN 2019 Hematologic Malignancies meeting.
Read Article
Selinexor-Dexamethasone Combination Improves Outcomes in Patients with Multiple Myeloma Refractory to 3 Drug Classes
In the Literature
December 2019, Vol 10, No 6
In the phase 2 STORM Part 1 clinical trial, 21% of patients with refractory multiple myeloma had a partial or better response to oral selinexor (Xpovio) plus dexamethasone. Those findings were the basis for the pivotal phase 2 STORM Part 2 study (Chari A, et al.
N Engl J Med
. 2019;381:727-738).
Read Article
Five-Year Survival Rates with BRAF-MEK Inhibitors in Metastatic Melanoma with BRAF Mutation
In the Literature
December 2019, Vol 10, No 6
The introduction of
BRAF
- and
MEK
-targeted therapies and immune checkpoint inhibitors has significantly improved outcomes in patients with metastatic melanoma. However, many patients have drug resistance—acquired or primary—which results in death from underlying disease.
Read Article
The Future of Cancer Care: Change Is the Only Certainty
AVBCC 2019 Summit
December 2019, Vol 10, No 6
New York, NY—By its very nature, oncology is rife with change, with new research resulting in treatment advances at a rapid pace. Pending federal legislation aimed at reining in prescription drug prices and an upcoming presidential election may introduce yet further changes in oncology. A discussion on these issues was presented at the 2019 AVBCC Summit in October, with a look at the oncology landscape.
Read Article
Payers' Perspectives on Value in Cancer Care
AVBCC 2019 Summit
December 2019, Vol 10, No 6
New York, NY—At the 2019 AVBCC Summit, a panel of payers, moderated by Mike Kolodziej, MD, Vice President, Chief Innovation Officer, ADVI Health, discussed strategies for improving the delivery of value-based cancer care, along with changes on the horizon as payers and providers strive to maximize access to high-quality oncology drugs.
Read Article
Barriers to Value-Based Contracting in Oncology
AVBCC 2019 Summit
December 2019, Vol 10, No 6
New York, NY—With drug-pricing legislations currently before the House and the Senate, the issue of demonstrating value in high-cost drug therapies has become the front and center of the healthcare conversation. Moderator Roger Longman, MA, Co-Founder and Chairman, Real Endpoints LLC, a reimbursement-focused analytics and advisory firm, engaged an expert panel on the topic of value-based agreements during the 2019 AVBCC Summit.
Read Article
Ensuring Patient Access to Cancer Care Must Be a Priority
AVBCC 2019 Summit
December 2019, Vol 10, No 6
New York, NY—Patients with cancer are not just faced with a terrifying disease; they must also surmount an uphill climb when it comes to accessing care. Advocates—some of whom have shared in their experiences as patients—are hard at work to ensure access is a reality. A roundtable discussion of patient advocates at the 2019 AVBCC Summit focused on identifying the major obstacles to care and what can be done to improve patient access.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma